A transdermal CRISPR/Cas9 strategy using biodegradable microneedles to target YB-1 in melanoma
Xiazhou Fu, Zhaoyi Chen, Ziru Zhang, Yufei Jiang, Xiaomeng Jiang, Yuxin Yang, Hongsheng Zhang, Xinyun Zou, Jingwen Luo · 2026
Read A transdermal CRISPR/Cas9 strategy using biodegradable microneedles to target YB-1 in melanoma by Xiazhou Fu, Zhaoyi Chen, Ziru Zhang, Yufei Jiang, Xiaomeng Jiang, Yuxin Yang, Hongsheng Zhang, Xinyun Zou, Jingwen Luo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579312.txt.
Description
Xiazhou Fu and co-authors deliver gene editing through the skin in 2026 to fight melanoma. Their target is YB-1, a gene that drives the cancer's growth, spread, and drug resistance. The editing kit rides in tiny particles on dissolvable microneedle patches, together with a chemo drug.
In cell tests the particles entered well, edited the gene in about two thirds of cells, and left only about 4 percent of tumor cells alive. In mice, patch treatment shrank tumor weight by over 92 percent against untreated controls. Organs showed little damage, suggesting the approach is safe. The patch offers a needle-free way to combine editing and chemo in one spot.
Catalog record
| CREATOR | Xiazhou Fu, Zhaoyi Chen, Ziru Zhang, Yufei Jiang, Xiaomeng Jiang, Yuxin Yang, Hongsheng Zhang, Xinyun Zou, Jingwen Luo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |